NPPB and atrial fibrillation: In the analysis of secondary outcomes, there is no clear correlation between ivabradine treatment and CVD mortality, QoL using the MLWHF questionnaire, NT-proBNP or BNP, and events such as CVD mortality, HF readmission, or development of atrial fibrillation [10-11].